Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTATE: Talquetamab and Teclistamab Consolidation in Newly Diagnosed Multiple Myeloma
NCT06993675Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of talquetamab, teclistamab in multiple myeloma (MM). Started Aug 2025; status: recruiting.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06993675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993675.